Herpes zoster in Belgium: a new solution to an old problem

Last updated on 29-5-2024 by Sherihane Bensemmane

Public Access

Published

Peer reviewed scientific article

Engels

Article written during project(s) : 

Samenvatting:

Herpes zoster (HZ) is caused by reactivation of the varicella-zoster virus. The life-time risk of developing HZ is ~ 30%. Management of HZ can be challenging due to limited efficacy of oral antivirals on pain control, and neuropathic pain that may require aggressive management. Post-herpetic neuralgia (PHN) can cause substantial pain and occurs in up to one-quarter of patients with HZ. Up to 48,000 HZ cases are estimated to occur annually in Belgium, estimated to cost almost 7 million euros in treatment. The recombinant zoster vaccine (RZV, Shingrix, GSK) was approved in Europe in 2017…

Associated health topics:

QR code

QR code for this page URL